Dyne Therapeutics (NASDAQ:DYN) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research report released on Friday morning, Benzinga reports. HC Wainwright currently has a $36.00 price target on the stock.

DYN has been the topic of several other reports. Piper Sandler upped their price objective on Dyne Therapeutics from $27.00 to $29.00 and gave the company an overweight rating in a research note on Wednesday, March 6th. Chardan Capital increased their price objective on Dyne Therapeutics from $20.00 to $31.00 and gave the stock a buy rating in a research note on Friday, March 8th. Morgan Stanley started coverage on shares of Dyne Therapeutics in a research note on Tuesday. They issued an overweight rating and a $40.00 target price on the stock. Oppenheimer reiterated an outperform rating and set a $47.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, March 26th. Finally, Stifel Nicolaus boosted their price target on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the company a buy rating in a research report on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of Moderate Buy and a consensus price target of $37.75.

Dyne Therapeutics Stock Performance

Shares of DYN traded up $0.08 on Friday, reaching $26.08. 761,928 shares of the stock traded hands, compared to its average volume of 818,946. The stock’s 50-day moving average price is $26.41 and its 200-day moving average price is $18.42. Dyne Therapeutics has a 12 month low of $6.40 and a 12 month high of $30.27.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, March 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.17). Sell-side analysts forecast that Dyne Therapeutics will post -3.27 EPS for the current year.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, major shareholder Venture Fund Xi L.P. Atlas sold 184,501 shares of the company’s stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $22.57, for a total transaction of $4,164,187.57. Following the transaction, the insider now owns 6,631,464 shares of the company’s stock, valued at approximately $149,672,142.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, insider Wildon Farwell sold 5,493 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $25.07, for a total value of $137,709.51. Following the transaction, the insider now owns 163,503 shares of the company’s stock, valued at approximately $4,099,020.21. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Venture Fund Xi L.P. Atlas sold 184,501 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $22.57, for a total transaction of $4,164,187.57. Following the sale, the insider now directly owns 6,631,464 shares of the company’s stock, valued at $149,672,142.48. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,875,432 shares of company stock worth $44,368,530. Corporate insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Wetzel Investment Advisors Inc. bought a new position in shares of Dyne Therapeutics in the 1st quarter worth $28,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Dyne Therapeutics by 58.5% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,379 shares of the company’s stock worth $75,000 after buying an additional 3,092 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Dyne Therapeutics by 95.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 9,310 shares of the company’s stock worth $83,000 after buying an additional 4,552 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of Dyne Therapeutics by 355.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock valued at $94,000 after acquiring an additional 5,541 shares during the last quarter. Finally, Principal Financial Group Inc. raised its position in shares of Dyne Therapeutics by 10.7% in the 3rd quarter. Principal Financial Group Inc. now owns 15,229 shares of the company’s stock valued at $136,000 after acquiring an additional 1,476 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.